MSLN and cancer: Anti-MSLN Ab-immunotoxins, developed for cancer therapy, were used to target human MSLN+ aPFs in vitro and in vivo, and successfully killed human aPFs, suggesting that immunotherapy-based targeting of MSLN+ tissue fibroblasts might provide a new strategy for treatment of cholestatic fibrosis and fibrosis in other organs.